RA0807

antibody from Oursmab
Targeting: VEGFA VEGF, VEGF-A, VPF
Provider product page for RA0807
Western blot
ELISA
Immunocytochemistry
Flow cytometry
Functional assay

Antibody data

Product number
RA0807 - Provider product page
Provider
Oursmab
Product name
Bevacizumab (Biosimilar Reference Antibody) (VEGFA)
Antibody type
Monoclonal
Description
Bevacizumab is a recombinant humanized monoclonal antibody (IgG1) that revolutionized cancer therapy as the first clinically approved angiogenesis inhibitor. It specifically targets and neutralizes vascular endothelial growth factor A (VEGF-A), a key signaling protein that stimulates the formation of new blood vessels (angiogenesis). By binding to VEGF-A, bevacizumab blocks its interaction with VEGF receptors (VEGFR-1 and VEGFR-2) on endothelial cells, thereby inhibiting tumor blood vessel growth. This ¡°starves¡± the tumor of oxygen and nutrients, suppresses metastasis, and normalizes existing abnormal tumor vasculature to improve drug delivery. It is approved for the treatment of various metastatic cancers, including colorectal, lung, ovarian, cervical, and renal cell cancers, as well as glioblastoma, and is used in combination with chemotherapy or as maintenance therapy.
Reactivity
Human
Isotype
IgG
Vial size
100 ¦Ìg,1 mg,5 mg,10 mg,25 mg,50 mg,100 mg
Concentration
Bottled at the concentration indicated on the vial.
Storage
Store at -20¡ãC or -80¡ãC. Avoid repeated freeze.
VEGFA protein structure - RA0807 shown in red.